Time to back British blue-chip stocks

UK blue-chip stocks are surging ahead. But the FTSE 100 offers a tasty yield and remains very reasonably priced compared with its major counterparts.


Global growth and a weak pound have boosted BP

What if they threw a party but nobody came? UK stocks are surging ahead, with the blue-chip index, the FTSE 100, reaching a new record peak just below 8,000 this week. The mid-cap index, the FTSE 250, has hit its own all-time high above 21,000.

Yet British fund managers have rarely been less keen on the UK equity market, according to a survey by Bank of America Merrill Lynch. Their view contrasts starkly with the attitude of US hedge-fund managers, or corporate raiders, according to Mark Atherton in The Times. "If I had to choose between the two, my money is with the corporate raiders," says Richard Buxton of Old Mutual.

A global tailwind

Earlier this month we highlighted the bargains among more domestically orientated companies. The blue-chips are also well worth considering. The constituents of the FTSE 100 derive around 70% of their sales from overseas, so the healthy global backdrop, coupled with the recent weakness in sterling (which boosts the value of foreign earnings), bodes very well.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up

Strong worldwide growth has already helped deliver record quarterly profits for the FTSE 350 (the blue-chips and the mid-caps combined) between January and March 2018, with the major multinationals that dominate the FTSE 100 performing especially strongly. They grew their sales by 30% year-on-year. BP's earnings soared by 71%.

The global economic recovery has been long but shallow, notes Fidelity's Tom Stevenson in The Daily Telegraph. That suggests there is still plenty of spare capacity, so further growth shouldn't lead to overheating anytime soon. And sterling seems unlikely to rebound significantly for now, given the prospect of a growing gap between US and UK interest rates and ongoing uncertainty over our eventual trade deal with the EU.

The FTSE 100 is also unusually geared to the mature stages of an economic and market cycle, adds Stevenson. It is skewed towards energy stocks, and commodities tend to thrive in the late phase of an upswing. The market is also especially exposed "to the kinds of less cyclical, higher-quality companies that typically do well as the bull market matures". One key sector is consumer staples, for example, while utilities and telecoms are also better represented than in other major markets.

FTSE 100 offers a juicy yield

The FTSE looks very reasonably priced compared with its major counterparts on a 2018 price-earnings ratio of 14, says AJ Bell's Russ Mould, and this is also reflected in a dividend yield of 4%, one of the highest among the world's major markets. "This beats cash and [the ten-year gilt's 1.5%] hands down." It is also higher than inflation. Reinvested dividends account for the vast majority of long-term returns, as the annual Barclays Equity Gilt study reminds us, so a healthy income stream is always welcome. We should see a stampede of bulls into the UK market soon.

Andrew Van Sickle

Andrew is the editor of MoneyWeek magazine. He grew up in Vienna and studied at the University of St Andrews, where he gained a first-class MA in geography & international relations.

After graduating he began to contribute to the foreign page of The Week and soon afterwards joined MoneyWeek at its inception in October 2000. He helped Merryn Somerset Webb establish it as Britain’s best-selling financial magazine, contributing to every section of the publication and specialising in macroeconomics and stockmarkets, before going part-time.

His freelance projects have included a 2009 relaunch of The Pharma Letter, where he covered corporate news and political developments in the German pharmaceuticals market for two years, and a multiyear stint as deputy editor of the Barclays account at Redwood, a marketing agency.

Andrew has been editing MoneyWeek since 2018, and continues to specialise in investment and news in German-speaking countries owing to his fluent command of the language.